"Product Profiles: Non-Insulin Antidiabetics - Options Abound as the SGLT-2 Class Prepares for Market Entry" - New Market Report
The 2012-21 forecast period will see the loss of exclusivity for the leading non-insulin antidiabetic Actos franchise, while new launches include the first once-weekly GLP-1 agonists and the oral SGLT-2 inhibitor class, to compete in an increasingly crowded treatment algorithm in type 2 diabetes.
View full press release